Key Takeaways Myriad Genetics' GeneSight test showed superiority over treatment-as-usual in major depression.A meta-analysis of six trials with 3,532 patients highlighted MYGN's GeneSight test's clinical benefits.Patients using MYGN's GeneSight were 41% more likely to achieve remission and 30% more likely to respond.Myriad Genetics, Inc. (MYGN) recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test o ...

Sera Prognostics (SERA) FY Conference September 05, 2025 07:00 AM ET Speaker1Hello everyone, and thank you for joining HC Wainwright's 27th Annual Global Investment Conference. My name is Vivian, and I'm an analyst on the Corporate Access team. HC Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. We have a total of 19 publishing senior analysts and over 650 compa ...

Core Insights - Intelligent Bio Solutions Inc. achieved record monthly cartridge sales in July 2025, with 519 boxes shipped, translating to over 12,500 cartridges and a 60% year-on-year growth [1][2]. Group 1: Business Model and Revenue Growth - Cartridges are a high-margin consumable in the Company's fingerprint sweat-based drug testing system, forming the basis of its razor/razor blade business model, which is experiencing growth due to new large contracts and an expanding global installed base [2][3]. - The Company secured a significant multi-site, high-volume contract in the transportation sector, which has increased ongoing demand for consumables [2]. - There is a growing pipeline of opportunities, with an increasing number of bids and tenders for large-scale deployments, indicating a robust demand for the Company's products [2]. Group 2: Management Insights - The President and CEO of Intelligent Bio Solutions highlighted that the record cartridge sales reflect the strength of the business model and the momentum from major contract wins, suggesting continued growth in cartridge demand and reliable revenue streams [3]. - The Company aims to leverage its installed base to drive recurring sales of cartridges while planning for U.S. market expansion beyond forensic use in the second half of 2025 [3]. Group 3: Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [4]. - The technology is designed to be hygienic and cost-effective, screening for drugs commonly found in the workplace, with quick sample collection and results [4]. - Current customer segments outside the U.S. include construction, manufacturing, transport, mining, and drug treatment organizations, indicating a diverse market presence [4].

Core Insights - Intelligent Bio Solutions Inc. reported a 16% year-on-year and quarter-on-quarter revenue growth in the fourth quarter of fiscal 2025, driven by increased demand for drug testing cartridges [1][5][7] - The company is focused on securing FDA 510(k) clearance for its opiate test system, which will allow for broader use beyond forensic settings in the U.S. market [4][6] - Fiscal 2025 was characterized by operational streamlining, higher-margin cartridge sales, and an expanding international customer base exceeding 450 accounts across 24 countries [2][3][11] Financial Performance - Revenue for the fiscal fourth quarter reached $843,884, up from $727,824 in the same quarter of the previous year, reflecting a 16% increase [7] - Total revenue for fiscal 2025 was $3,052,532, a slight decrease from $3,111,781 in fiscal 2024 [17] - The company reported a net loss of $10,568,733 for fiscal 2025, compared to a net loss of $10,156,759 in fiscal 2024 [17] Operational Highlights - The company secured 115 new accounts in fiscal 2025, contributing to a total of over 450 active customer accounts [11] - Revenue from cartridge sales increased by 24% year-on-year in the fourth quarter and 14% year-on-year for the full fiscal year [7] - The company implemented measures to improve gross margins and reduce net loss, including product enhancements and manufacturing improvements [8] Regulatory and Market Expansion - The company is actively working on its regulatory strategy to secure FDA clearance, which includes engaging with regulatory consultants and refining clinical study designs [4][6] - Efforts to expand into international markets are ongoing, with active scoping in Canada, Indonesia, and the Philippines [6] - The company aims to expand its commercial presence in the U.S. market, which is the largest drug screening market globally [3][4]

Core Insights - Veracyte, Inc. (VCYT) reported second-quarter 2025 adjusted earnings of 44 cents per share, a significant increase of 46.7% from 30 cents in the same period last year, exceeding the Zacks Consensus Estimate by 41.9% [1][7] - The company's revenues rose 13.8% year over year to $130.2 million, surpassing the Zacks Consensus Estimate by 7.1% [2][7] Revenue Breakdown - Testing revenues reached $122.3 million, reflecting a 14% year-over-year increase, driven by Decipher and Afirma revenue growth of 24% and 5%, respectively [3] - Product revenues decreased by 8% year over year to $3.6 million [3] - Biopharmaceutical and other revenues increased by 21% to $4.3 million compared to the prior-year quarter [3] Margins and Expenses - Total cost of revenues was $37.7 million, up 12.3% year over year [4] - Gross profit increased by 14.4% to $92.4 million, with gross margin expanding by 38 basis points to 71% [4] - Selling and marketing expenses rose 4.5% to $25.3 million, while general and administrative expenses increased by 1.8% to $32.3 million [4] - R&D expenses totaled $16.3 million, down 1.2% year over year [4] - Adjusted operating margin improved by 689 basis points to 14.2% [4] Cash and Capital Structure - Veracyte ended Q2 2025 with cash and cash equivalents of $219.5 million, up from $186.1 million at the end of Q1 [5] - Cumulative net cash from operating activities was $39 million, compared to $20.6 million a year ago [5] Guidance - The company raised its full-year 2025 testing revenue guidance to a range of $477-$483 million, indicating a year-over-year growth of 14% to 15% [6] - Total revenue guidance for 2025 was also increased to $496-$504 million, implying 11% to 13% year-over-year growth [8] - Adjusted EBITDA as a percentage of revenues is anticipated to be approximately 23.5%, up from the previous guidance of 22.5% [8] Notable Developments - The launch of Decipher Prostate Metastatic Genomic Classifier for patients with advanced prostate cancer was a significant development in Q2 [10]

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [3] - The company aims to revolutionize portable testing through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [3] - The system is designed to be hygienic and cost-effective, screening for recent drug use including opiates, cocaine, methamphetamine, and cannabis [3] Technology and Applications - The Intelligent Fingerprinting Drug Screening System allows for sample collection in seconds and provides results in under ten minutes [3] - This technology is particularly valuable for employers in safety-critical industries, enhancing workplace safety [3] - Current customer segments outside the US include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [3] Upcoming Events - The management team will participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025 [1] - A presentation is scheduled for August 21, 2025, at 9:15 a.m. Eastern Time [2] - Interested parties can register for the conference through a provided link and schedule one-on-one meetings with the management team [2]

Group 1 - Cannabix Technologies Inc. has appointed William R. Corl to its board of directors, who is the CEO of Omega Laboratories, a leading drug testing laboratory [1][2] - Cannabix and Omega have been collaborating since May 2024 to commercialize the Marijuana Breath Test (MBT) technology [1][5] - Omega Laboratories has over twenty years of experience in forensic drug testing and holds multiple international certifications [4] Group 2 - Mr. Corl has extensive experience in technology management and has been influential in advancing drug screening regulations [2][3] - The partnership between Cannabix and Omega includes efforts in marketing, distribution, and logistics for the MBT [5] - Cannabix focuses on developing breath testing technologies for recent marijuana use and has also created an alcohol screening device [6]

Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on transforming care for patients with chronic autoimmune conditions [2] - The company's flagship product, AVISE CTD, aids in the early and accurate diagnosis of complex autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's disease [2] - Exagen specializes in testing for rheumatic diseases, offering a comprehensive suite of AVISE-branded tests for diagnosis, prognosis, and monitoring [2] Upcoming Events - Exagen management will participate in the Canaccord Genuity 45 Annual Growth Conference on August 12, 2025, in Boston, MA, featuring a fireside chat and 1X1 meetings [1] - The company will also attend the Cantor Global Healthcare Conference 2025 on September 3, 2025, in New York, NY, with similar participation formats [1]

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securit ...

Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening SystemNEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or prepay the exercise price) certain existing warrants to purchase up to 2,023,228 share ...